 | • レポートコード：GIR-2104Z09722 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、骨髄増殖性疾患治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。骨髄増殖性疾患治療薬の種類別市場規模（Ph+CML、Ph-MPN）、用途別市場規模（病院、薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・骨髄増殖性疾患治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Celgene、Bristol-Myers Squibb、Gamida Cell、Incyte、Geron、Promedior、Johnson and Johnson ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：Ph+CML、Ph-MPN ・用途別分析2016年-2026年：病院、薬局 ・骨髄増殖性疾患治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・骨髄増殖性疾患治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・骨髄増殖性疾患治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・骨髄増殖性疾患治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・骨髄増殖性疾患治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Myeloproliferative Disorders Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Myeloproliferative Disorders Drugs size is estimated to be USD 7146 million in 2025 from USD 6642.1 million in 2019, with a change XX% between 2019 and 2020. The global Myeloproliferative Disorders Drugs market size is expected to grow at a CAGR of 1.8% for the next five years.
Market segmentation
Myeloproliferative Disorders Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Ph+ CML
Ph- MPN
Market segment by Application, can be divided into
Hospitals
Pharmacy
Market segment by players, this report covers
Celgene
Bristol-Myers Squibb
Gamida Cell
Incyte
Geron
Promedior
Johnson and Johnson
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Myeloproliferative Disorders Drugs
1.2 Classification of Myeloproliferative Disorders Drugs by Type
1.2.1 Overview: Global Myeloproliferative Disorders Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Myeloproliferative Disorders Drugs Revenue Market Share by Type in 2020
1.2.3 Ph+ CML
1.2.4 Ph- MPN
1.3 Global Myeloproliferative Disorders Drugs Market by Application
1.3.1 Overview: Global Myeloproliferative Disorders Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Pharmacy
1.4 Global Myeloproliferative Disorders Drugs Market Size & Forecast
1.5 Global Myeloproliferative Disorders Drugs Market Size and Forecast by Region
1.5.1 Global Myeloproliferative Disorders Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Myeloproliferative Disorders Drugs Market Size by Region, (2016-2021)
1.5.3 North America Myeloproliferative Disorders Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Myeloproliferative Disorders Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Myeloproliferative Disorders Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Myeloproliferative Disorders Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Myeloproliferative Disorders Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Myeloproliferative Disorders Drugs Market Drivers
1.6.2 Myeloproliferative Disorders Drugs Market Restraints
1.6.3 Myeloproliferative Disorders Drugs Trends Analysis
2 Company Profiles
2.1 Celgene
2.1.1 Celgene Details
2.1.2 Celgene Major Business
2.1.3 Celgene Myeloproliferative Disorders Drugs Product and Solutions
2.1.4 Celgene Myeloproliferative Disorders Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Celgene Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Product and Solutions
2.2.4 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 Gamida Cell
2.3.1 Gamida Cell Details
2.3.2 Gamida Cell Major Business
2.3.3 Gamida Cell Myeloproliferative Disorders Drugs Product and Solutions
2.3.4 Gamida Cell Myeloproliferative Disorders Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Gamida Cell Recent Developments and Future Plans
2.4 Incyte
2.4.1 Incyte Details
2.4.2 Incyte Major Business
2.4.3 Incyte Myeloproliferative Disorders Drugs Product and Solutions
2.4.4 Incyte Myeloproliferative Disorders Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Incyte Recent Developments and Future Plans
2.5 Geron
2.5.1 Geron Details
2.5.2 Geron Major Business
2.5.3 Geron Myeloproliferative Disorders Drugs Product and Solutions
2.5.4 Geron Myeloproliferative Disorders Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Geron Recent Developments and Future Plans
2.6 Promedior
2.6.1 Promedior Details
2.6.2 Promedior Major Business
2.6.3 Promedior Myeloproliferative Disorders Drugs Product and Solutions
2.6.4 Promedior Myeloproliferative Disorders Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Promedior Recent Developments and Future Plans
2.7 Johnson and Johnson
2.7.1 Johnson and Johnson Details
2.7.2 Johnson and Johnson Major Business
2.7.3 Johnson and Johnson Myeloproliferative Disorders Drugs Product and Solutions
2.7.4 Johnson and Johnson Myeloproliferative Disorders Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Johnson and Johnson Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Myeloproliferative Disorders Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Myeloproliferative Disorders Drugs Players Market Share
3.2.2 Top 10 Myeloproliferative Disorders Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Myeloproliferative Disorders Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Myeloproliferative Disorders Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Myeloproliferative Disorders Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Myeloproliferative Disorders Drugs Revenue Market Share by Application (2016-2021)
5.2 Myeloproliferative Disorders Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Myeloproliferative Disorders Drugs Revenue by Type (2016-2026)
6.2 North America Myeloproliferative Disorders Drugs Revenue by Application (2016-2026)
6.3 North America Myeloproliferative Disorders Drugs Market Size by Country
6.3.1 North America Myeloproliferative Disorders Drugs Revenue by Country (2016-2026)
6.3.2 United States Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Myeloproliferative Disorders Drugs Revenue by Type (2016-2026)
7.2 Europe Myeloproliferative Disorders Drugs Revenue by Application (2016-2026)
7.3 Europe Myeloproliferative Disorders Drugs Market Size by Country
7.3.1 Europe Myeloproliferative Disorders Drugs Revenue by Country (2016-2026)
7.3.2 Germany Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
7.3.3 France Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Myeloproliferative Disorders Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Myeloproliferative Disorders Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Myeloproliferative Disorders Drugs Market Size by Region
8.3.1 Asia-Pacific Myeloproliferative Disorders Drugs Revenue by Region (2016-2026)
8.3.2 China Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
8.3.5 India Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Myeloproliferative Disorders Drugs Revenue by Type (2016-2026)
9.2 South America Myeloproliferative Disorders Drugs Revenue by Application (2016-2026)
9.3 South America Myeloproliferative Disorders Drugs Market Size by Country
9.3.1 South America Myeloproliferative Disorders Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Myeloproliferative Disorders Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Myeloproliferative Disorders Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Myeloproliferative Disorders Drugs Market Size by Country
10.3.1 Middle East & Africa Myeloproliferative Disorders Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Myeloproliferative Disorders Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Myeloproliferative Disorders Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Myeloproliferative Disorders Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Myeloproliferative Disorders Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Myeloproliferative Disorders Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Myeloproliferative Disorders Drugs Revenue Market Share by Region (2021-2026)
Table 6. Celgene Corporate Information, Head Office, and Major Competitors
Table 7. Celgene Major Business
Table 8. Celgene Myeloproliferative Disorders Drugs Product and Solutions
Table 9. Celgene Myeloproliferative Disorders Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Major Business
Table 12. Bristol-Myers Squibb Myeloproliferative Disorders Drugs Product and Solutions
Table 13. Bristol-Myers Squibb Myeloproliferative Disorders Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Gamida Cell Corporate Information, Head Office, and Major Competitors
Table 15. Gamida Cell Major Business
Table 16. Gamida Cell Myeloproliferative Disorders Drugs Product and Solutions
Table 17. Gamida Cell Myeloproliferative Disorders Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Incyte Corporate Information, Head Office, and Major Competitors
Table 19. Incyte Major Business
Table 20. Incyte Myeloproliferative Disorders Drugs Product and Solutions
Table 21. Incyte Myeloproliferative Disorders Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Geron Corporate Information, Head Office, and Major Competitors
Table 23. Geron Major Business
Table 24. Geron Myeloproliferative Disorders Drugs Product and Solutions
Table 25. Geron Myeloproliferative Disorders Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Promedior Corporate Information, Head Office, and Major Competitors
Table 27. Promedior Major Business
Table 28. Promedior Myeloproliferative Disorders Drugs Product and Solutions
Table 29. Promedior Myeloproliferative Disorders Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Johnson and Johnson Corporate Information, Head Office, and Major Competitors
Table 31. Johnson and Johnson Major Business
Table 32. Johnson and Johnson Myeloproliferative Disorders Drugs Product and Solutions
Table 33. Johnson and Johnson Myeloproliferative Disorders Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Global Myeloproliferative Disorders Drugs Revenue (USD Million) by Players (2019-2021)
Table 35. Global Myeloproliferative Disorders Drugs Revenue Share by Players (2019-2021)
Table 36. Breakdown of Myeloproliferative Disorders Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 37. Myeloproliferative Disorders Drugs Players Head Office, Products and Services Provided
Table 38. Myeloproliferative Disorders Drugs Mergers & Acquisitions in the Past Five Years
Table 39. Myeloproliferative Disorders Drugs New Entrants and Expansion Plans
Table 40. Global Myeloproliferative Disorders Drugs Revenue (USD Million) by Type (2016-2021)
Table 41. Global Myeloproliferative Disorders Drugs Revenue Share by Type (2016-2021)
Table 42. Global Myeloproliferative Disorders Drugs Revenue Forecast by Type (2021-2026)
Table 43. Global Myeloproliferative Disorders Drugs Revenue by Application (2016-2021)
Table 44. Global Myeloproliferative Disorders Drugs Revenue Forecast by Application (2021-2026)
Table 45. North America Myeloproliferative Disorders Drugs Revenue by Type (2016-2021) & (USD Million)
Table 46. North America Myeloproliferative Disorders Drugs Revenue by Type (2021-2026) & (USD Million)
Table 47. North America Myeloproliferative Disorders Drugs Revenue by Application (2016-2021) & (USD Million)
Table 48. North America Myeloproliferative Disorders Drugs Revenue by Application (2021-2026) & (USD Million)
Table 49. North America Myeloproliferative Disorders Drugs Revenue by Country (2016-2021) & (USD Million)
Table 50. North America Myeloproliferative Disorders Drugs Revenue by Country (2021-2026) & (USD Million)
Table 51. Europe Myeloproliferative Disorders Drugs Revenue by Type (2016-2021) & (USD Million)
Table 52. Europe Myeloproliferative Disorders Drugs Revenue by Type (2021-2026) & (USD Million)
Table 53. Europe Myeloproliferative Disorders Drugs Revenue by Application (2016-2021) & (USD Million)
Table 54. Europe Myeloproliferative Disorders Drugs Revenue by Application (2021-2026) & (USD Million)
Table 55. Europe Myeloproliferative Disorders Drugs Revenue by Country (2016-2021) & (USD Million)
Table 56. Europe Myeloproliferative Disorders Drugs Revenue by Country (2021-2026) & (USD Million)
Table 57. Asia-Pacific Myeloproliferative Disorders Drugs Revenue by Type (2016-2021) & (USD Million)
Table 58. Asia-Pacific Myeloproliferative Disorders Drugs Revenue by Type (2021-2026) & (USD Million)
Table 59. Asia-Pacific Myeloproliferative Disorders Drugs Revenue by Application (2016-2021) & (USD Million)
Table 60. Asia-Pacific Myeloproliferative Disorders Drugs Revenue by Application (2021-2026) & (USD Million)
Table 61. Asia-Pacific Myeloproliferative Disorders Drugs Revenue by Region (2016-2021) & (USD Million)
Table 62. Asia-Pacific Myeloproliferative Disorders Drugs Revenue by Region (2021-2026) & (USD Million)
Table 63. South America Myeloproliferative Disorders Drugs Revenue by Type (2016-2021) & (USD Million)
Table 64. South America Myeloproliferative Disorders Drugs Revenue by Type (2021-2026) & (USD Million)
Table 65. South America Myeloproliferative Disorders Drugs Revenue by Application (2016-2021) & (USD Million)
Table 66. South America Myeloproliferative Disorders Drugs Revenue by Application (2021-2026) & (USD Million)
Table 67. South America Myeloproliferative Disorders Drugs Revenue by Country (2016-2021) & (USD Million)
Table 68. South America Myeloproliferative Disorders Drugs Revenue by Country (2021-2026) & (USD Million)
Table 69. Middle East & Africa Myeloproliferative Disorders Drugs Revenue by Type (2016-2021) & (USD Million)
Table 70. Middle East & Africa Myeloproliferative Disorders Drugs Revenue by Type (2021-2026) & (USD Million)
Table 71. Middle East & Africa Myeloproliferative Disorders Drugs Revenue by Application (2016-2021) & (USD Million)
Table 72. Middle East & Africa Myeloproliferative Disorders Drugs Revenue by Application (2021-2026) & (USD Million)
Table 73. Middle East & Africa Myeloproliferative Disorders Drugs Revenue by Country (2016-2021) & (USD Million)
Table 74. Middle East & Africa Myeloproliferative Disorders Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Myeloproliferative Disorders Drugs Picture
Figure 2. Global Myeloproliferative Disorders Drugs Revenue Market Share by Type in 2020
Figure 3. Ph+ CML
Figure 4. Ph- MPN
Figure 5. Myeloproliferative Disorders Drugs Revenue Market Share by Application in 2020
Figure 6. Hospitals Picture
Figure 7. Pharmacy Picture
Figure 8. Global Myeloproliferative Disorders Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 9. Global Myeloproliferative Disorders Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 10. Global Myeloproliferative Disorders Drugs Revenue Market Share by Region (2016-2026)
Figure 11. Global Myeloproliferative Disorders Drugs Revenue Market Share by Region in 2020
Figure 12. North America Myeloproliferative Disorders Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 13. Europe Myeloproliferative Disorders Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Asia-Pacific Myeloproliferative Disorders Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. South America Myeloproliferative Disorders Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Myeloproliferative Disorders Drugs Market Drivers
Figure 17. Myeloproliferative Disorders Drugs Market Restraints
Figure 18. Myeloproliferative Disorders Drugs Market Trends
Figure 19. Celgene Recent Developments and Future Plans
Figure 20. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 21. Gamida Cell Recent Developments and Future Plans
Figure 22. Incyte Recent Developments and Future Plans
Figure 23. Geron Recent Developments and Future Plans
Figure 24. Promedior Recent Developments and Future Plans
Figure 25. Johnson and Johnson Recent Developments and Future Plans
Figure 27. Global Myeloproliferative Disorders Drugs Revenue Share by Players in 2020
Figure 28. Myeloproliferative Disorders Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 29. Global Top 3 Players Myeloproliferative Disorders Drugs Revenue Market Share in 2020
Figure 30. Global Top 10 Players Myeloproliferative Disorders Drugs Revenue Market Share in 2020
Figure 31. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 32. Global Myeloproliferative Disorders Drugs Revenue Share by Type in 2020
Figure 33. Global Myeloproliferative Disorders Drugs Market Share Forecast by Type (2021-2026)
Figure 34. Global Myeloproliferative Disorders Drugs Revenue Share by Application in 2020
Figure 35. Global Myeloproliferative Disorders Drugs Market Share Forecast by Application (2021-2026)
Figure 36. North America Myeloproliferative Disorders Drugs Sales Market Share by Type (2016-2026)
Figure 37. North America Myeloproliferative Disorders Drugs Sales Market Share by Application (2016-2026)
Figure 38. North America Myeloproliferative Disorders Drugs Revenue Market Share by Country (2016-2026)
Figure 39. United States Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 40. Canada Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Mexico Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Europe Myeloproliferative Disorders Drugs Sales Market Share by Type (2016-2026)
Figure 43. Europe Myeloproliferative Disorders Drugs Sales Market Share by Application (2016-2026)
Figure 44. Europe Myeloproliferative Disorders Drugs Revenue Market Share by Country (2016-2026)
Figure 45. Germany Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. France Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. United Kingdom Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Russia Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Italy Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Asia-Pacific Myeloproliferative Disorders Drugs Sales Market Share by Type (2016-2026)
Figure 51. Asia-Pacific Myeloproliferative Disorders Drugs Sales Market Share by Application (2016-2026)
Figure 52. Asia-Pacific Myeloproliferative Disorders Drugs Revenue Market Share by Region (2016-2026)
Figure 53. China Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Japan Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. South Korea Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. India Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Southeast Asia Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Australia Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. South America Myeloproliferative Disorders Drugs Sales Market Share by Type (2016-2026)
Figure 60. South America Myeloproliferative Disorders Drugs Sales Market Share by Application (2016-2026)
Figure 61. South America Myeloproliferative Disorders Drugs Revenue Market Share by Country (2016-2026)
Figure 62. Brazil Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Argentina Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Middle East and Africa Myeloproliferative Disorders Drugs Sales Market Share by Type (2016-2026)
Figure 65. Middle East and Africa Myeloproliferative Disorders Drugs Sales Market Share by Application (2016-2026)
Figure 66. Middle East and Africa Myeloproliferative Disorders Drugs Revenue Market Share by Country (2016-2026)
Figure 67. Turkey Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Saudi Arabia Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. UAE Myeloproliferative Disorders Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Methodology
Figure 71. Research Process and Data Source
世界の呼吸器疾患治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Respiratory Disorders Drugs Market The global Respiratory Disorders Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity…- 世界の造血系疾患用治療薬・診断市場規模・現状・予測（2021年-2027年） Hematological disorders deal with blood related diseases and generally affect the quantity or functionality of the cells or proteins present in the blood. Some blood disorders result in the increase of the number of cells in blood such as anemia, leukopenia while other cause the number of blood cell…
- 世界の筋骨格系障害治療市場規模・現状・予測（2021年-2027年） Musculoskeletal Disorders or MSDs are injuries anddisorders that affect the human body's movement ormusculoskeletal system (i.e. muscles, tendons, ligaments, nerves, discs, blood vessels, etc.). Common MSDs include: Carpal Tunnel Syndrome. Tendonitis. Muscle / Tendon Market Analysis and Insights: G…
- 世界のパニック障害市場規模・現状・予測（2021年-2027年） Panic disorder is an anxiety disorder characterized by reoccurring unexpected panic attacks. Panic disorder is usually treated with counselling and medications. The type of counselling used is typically cognitive behavioral therapy which is effective in more than half of people. Medications used inc…
- 世界の神経精神障害＆治療市場規模・現状・予測（2021年-2027年） Neuropsychiatric disorder is a blanket medical term that encompasses a broad range of medical conditions that involve both neurology and psychiatry. Common neuropsychiatric disorders include seizures, attention deficits, cognitive deficits, palsies, uncontrolled anger, migraine headaches, addictions…